Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 3c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $60.9 million versus the consensus estimate of $59.57 million.

"We had another year of outstanding commercial growth," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "I have never been more excited about the opportunities ahead with our relentless focus on developing innovative therapies for patients in need."

GUIDANCE:

Vanda Pharmaceuticals sees FY2020 revenue of $240-260 million, versus the consensus of $274.6 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus